S. VELLALATH, K. N. VAN, D. ROMO* (TEXAS A&M UNIVERSITY, COLLEGE STATION, USA)
Direct Catalytic Asymmetric Synthesis of N-Heterocycles from Commodity Acid Chlorides by Employing α,β -Unsaturated Acylammonium Salts
Angew. Chem. Int. Ed. **2013**, DOI: 10.1002/anie.201306050.

Asymmetric Organocatalytic Synthesis of Lactams and Lactones

Selected examples: pyrrolidinones and piperidinones

catalyst: **3b**
bases:

LiHMDS (1 equiv)
DBU (1 equiv)
solvent: THF
conditions: $-30\text{ }^{\circ}\text{C}$, 18 h

Selected examples: enol δ -lactones

catalyst: **3a**, **3c**
bases:

LiHMDS (1 equiv)
DBU (1 equiv)
solvent: THF
conditions: $-30\text{ }^{\circ}\text{C}$, 18 h

Example: 3,4-dihydro-2-pyridinones

catalyst **3b**
base: DIPEA (3 equiv)
additive: LiCl (1 equiv)
4 Å MS
solvent: PhMe
conditions: $23\text{ }^{\circ}\text{C}$, 20 h

Significance: The reported method for the synthesis of lactams and lactones **4** employs quinine- and quinidine-derived catalysts **3** to activate α,β -unsaturated acid chlorides **1** toward reaction with bisnucleophiles **2**. A variety of heterocycles relevant to medicinal and natural product chemistry were obtained, including 2-pyrrolidinones, 2-piperidinones, enol δ -valerolactones, and 3,4-dihydro-2-pyridinones. The yields are modest to good and enantioselectivity is good to excellent. The method was demonstrated to provide two intermediates for drug synthesis (one on a gram scale).

Comment: For success of the reported method, significant tuning of the reaction conditions to the substrate, including the use of excess reactant; the choice of base, catalyst, and temperature; and the use of additives, is required. Catalyst **3b** affords products of opposite configuration to those obtained using **3a** or **3c**; although, in our opinion, the publication relies too heavily on assumptions in drawing this conclusion. In the synthesis of piperidinones, a retro-aza Michael side reaction results in low yields of the desired product. Interestingly, Michael addition, not acylation, appears to be the first mechanistic step, a fact essential to explaining the enantioselectivity.

SYNFACTS Contributors: Victor Snieckus, Benjamin N. Roche (Pfizer)
Synfacts 2014, 10(1), 0022 Published online: 13.12.2013
DOI: 10.1055/s-0033-1340427; Reg-No.: V15813SF